| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Sanofi backs 2 more documentary films about rare blood disorders | ||
| Fr | With Novo's semaglutide going off patent, Indian drugmakers set to launch their cheaper generics | ||
| Fr | ACIP member's miscommunication on vaccine panel's future adds to confusion after court ruling | ||
| Fr | Rhythm's Imcivree scores 'transformative' FDA approval in brain-damage related obesity | ||
| Do | CSL warns of supply shortfall, treatment delays for hemophilia gene therapy Hemgenix | ||
| Do | Novo's Wegovy HD passes muster under FDA national priority voucher program | ||
| Do | Maryland bill calls for more transparency in pharma's disease awareness campaigns | ||
| Do | Collegium ponies up $650M to gain ADHD drug Azstarys from Corium | ||
| Do | After Alfasigma's GSK licensing deal, Lynavoy picks up FDA nod in rare liver disease | ||
| Do | AstraZeneca to build cell therapy manufacturing hub, R&D center in Shanghai | ||
| Do | CDMO Axplora to pump $60M into Italian complex API plant | ||
| Mi | With downgrade, HSBC casts doubt about Lilly's 'stairway to heaven' trajectory | ||
| Mi | TrumpRx's 'world's lowest' drug price claims fall short in global comparison: NYT | ||
| Mi | J&J, Protagonist's 'game-changer' once-daily psoriasis pill Icotyde nabs FDA approval | ||
| Mi | BMS brings 'Emily in Paris' star and cancer survivor Ashley Park aboard campaign honoring oncologists | ||
| Mi | Sandoz expands biosim collab with Samsung Bioepis, sets sights on Takeda's Entyvio | ||
| Mi | Gates-backed TerraPower Isotopes blueprints $450M plant to supply next wave of radiopharmaceuticals | ||
| Di | GSK's management of Flovent allowed it to 'game the system': Hassan | ||
| Di | Indiana homes in on life sciences with $1B growth strategy, plan to create 100K jobs | ||
| Di | Hologic finds women's health stagnating over five years of global surveys | ||
| Di | Fierce Madness: Get your picks in for the 1st round of the 2026 Drug Name Tournament | ||
| Di | Moderna CEO Stéphane Bancel's 2025 pay hits $19.9M as cash bonus more than doubles | ||
| Di | Rhythm's Imcivree loses tempo across 4 rare genetic obesities, delivering phase 3 flop | ||
| Di | As Iran war squeezes Middle East drug shipments, experts warn of longer-term effects on US manufacturing, generics | ||
| Di | BioVie plans $20M IPO for spinout tasked with developing liver disease drug |